Med-I-Mark Tech Ltd.

Investment Analysis and Recommendations

Jeff Nelson
012278393

Executive Summary

This report evaluates four potential investment opportunities for Med-I-Mark Tech Ltd, using key financial metrics including Net Present Value (NPV), Internal Rate of Return (IRR), Debt Service Coverage Ratio (DSCR), and Modified Internal Rate of Return (MIRR). The analysis was conducted across three scenarios: base case (unadjusted cash flows), with financing (considering interest expense), and after-tax impacts. The goal was to determine which investments align best with Med-I-Mark's financial and strategic objectives.

Investment A (upgrading manufacturing facilities in Germany) was found to be **financially unviable** due to negative NPV, low IRR, and poor profitability index (PI), both in the base case and under financing. Despite the strategic importance of the region, the financial outlook does not justify the investment.

- **Undiscounted Cash Flow:** $4,000,000
- **NPV:** ($3,802,783)
- **IRR:** 4.45%

Investment B (acquiring competitor assets in Australia) offers strategic growth in a profitable market but exhibits narrow profitability and heightened risk when cash flow expenses are factored in. It is **recommended** with caution, due to its strategic value but limited financial returns.

- **Undiscounted Cash Flow:** $23,000,000
- **NPV:** $335,330
- **IRR:** 14.40%

Investment C (Launching a new medical device) emerged as the most attractive option. The project displays strong financial metrics, including high NPV, IRR, and PI, along with rapid payback. Even after considering financing and tax implications, Investment C remains **highly profitably** and strategically valuable, positioning Med-I-Mark for significant market impact.

- **Undiscounted Cash Flow:** $35,500,000
- **NPV:** $ $22,964,648
- **IRR:** 176.68%

Investment D (enhancing existing products) showed mixed results. It is **recommended** if funded through stock or cash financing. However, the project shows weak financial performance under financing scenarios.

- **Undiscounted Cash Flow:** $3,000,000
- **NPV:** $129,669
- **IRR:** 10.18%

Overall, the recommended Investments (B, C, and D) require $12,660,000 in bond financing, $9,878,100 in stock financing, and $4,500,000 used in a line of credit for a total debt burden of $27,038,100. With a total interest burden of $1,119,600 annually, Med-I-Mark is advised to proceed carefully with these investments, allocating capital efficiently while managing associated financial risks.

Glossary of Metrics

- **After Tax Cost of Debt:** Represents the effective cost of debt after taking into account tax savings due to interest deductibility. A lower after-tax cost of debt is favorable as it implies reduced financing costs.
  Formula: After-Tax Cost of Debt = Interest Rate x (1 – Tax Rate)

- **Debt Service Coverage Ratio (DSCR):** Measures the company's ability to cover debt payments with its operating income. A DSCR greater than 1.0 indicates sufficient cash flow to meet debt obligations.
  Formula: DSCR = Operating Cash Flow / Debt Service

- **Internal Rate of Return (IRR):** The discount rate that makes the NPV of all cash flows from a project equal to zero. A higher IRR compared to the required rate of return suggests a worthwhile investment.

- **Modified Internal Rate of Return (MIRR):** A modified version of IRR that accounts for the cost of borrowing and reinvestment rate of the project's cash flows. MIRR provides a more accurate reflection of the project's profitability. A higher MIRR indicates a better return.
  Formula: MIRR = (Terminal Value of Positive Cash Flows / Present Value of Negative Cash Flows)^(1/n) – 1

- **Net Present Value (NPV):** Represents the value of projected cash flows discounted back to their present value. A positive NPV indicates that the project is expected to generate value beyond its cost. Typically, an NPV greater than zero is desirable.
  Formula: NPV = ∑ (Cash Flow / (1 + Discount Rate)^n) - Initial Investment

- **Payback Period:** the time it takes for an investment to generate cash flows sufficient to recover the initial investment. A shorter payback period is preferred as it pays back the initial investment quicker.
  Formula: Payback Period = Initial Investment / Annual Cash Inflows

- **Weighted Average Cost of Capital (WACC):** The average rate of return a company is expected to pay its investors; it is a weighted average of the cost of equity and the after-tax cost of debt. A lower WACC indicates that the company's financing costs are relatively inexpensive, which improves the NPV of investment projects.
  Formula: WACC = (E/V * Ec) + (D/V * Dc * (1 – Tax Rate)), where E is equity, D is debt, V is total value, Ec is cost of Equity, and Dc is cost of debt.

Investment Analysis for Med-I-Mark Tech Ltd.

Med-I-Mark Tech Ltd has been presented with four prospective investment opportunities, each evaluated to determine their viability based on key financial metrics such as Net Present Value (NPV), Internal Rate of Return (IRR), Debt Service Coverage Ratio (DSCR), Payback Period, Profitability Index (PI), Modified Internal Rate of Return (MIRR), and Weighted Average Cost of Capital (WACC). Metrics like NPV, PI, and MIRR are evaluated using both the WACC and the Required Rate of Return to provide a comprehensive view of each investments viability. We will look at each investment under a lens of a "Base" case with unadjusted cash flows and no financing expenses taken into consideration. Then "With Financing" that considers the interest rate expense. Finally, the "After Tax" case will take all known factors from financing costs to after-tax profit, ultimately providing insight into the net profit of the investment. The aim is to identify which investments best align with shareholder expectations, considering both financial viability and strategic fit for the company.

Investment A: Upgrade Manufacturing Facilities in Germany

Investment A (Upgrade Germany)			
Initial Investment	**Cash Flow**	**Undiscounted Cash Flow**	**After-tax Debt Cost**
($10,000,000)	$1,400,000	$4,000,000	4.8%
Metric	**Base**	**With Financing**	**After Taxes**
NPV	($3,802,783)	($6,133,388)	($7,127,779)
IRR	4.45%	-2.69%	-6.31%
MIRR	9.32%	5.20%	2.88%
PI	0.66	0.45	0.36
DSCR	3.13	2.13	1.71

Investment A involves upgrading the manufacturing facilities in Germany, the smallest of Med-I-Mark's production sites, but a key supplier to the Middle East market. The initial investment required is $10 million, expected to yield annual cash flows of $1.4 million over the next ten years. The financing structure includes a 70/30 bond to stock ratio, resulting in a final fund amount of $7,446,809 in bonds and $3,658,537 in stock after considering par rate costs. The undiscounted cash flow is $4 million, and the after-tax cost of debt is 4.8%.

Base Case

Upon analysis, the Net Present Value (NPV) of Investment A was calculated to be -$3,802,783, indicating that the project would ultimately reduce shareholder wealth. The Internal Rate of Return (IRR) is 4.45%, which is significantly below the required rate of return of 14%. The Profitability Index (PI) is also unsatisfactory at 0.66, which suggests that for every dollar invested, less than a dollar would be generated in return.

With Financing

The annual interest payment on the bonds is $446,809, calculated using an interest rate of 6%, adding further financial burden without sufficient expected returns. Under the financing scenario, the Net Present Value (NPV) decreases compared to the Base Case, remaining negative at -$6,133,388. The Internal Rate of Return (IRR) also drops to -2.69%, reflecting the impact of interest payments, and remains significantly below the required rate of return. The Profitability Index (PI) falls to 0.45, indicating that the project becomes even less attractive when considering the cost of financing. Overall, financing worsens the project's financial metrics and makes it even less viable.

After Taxes

After considering the tax impact, the effective cash flow reduces, which significantly affects the overall metrics. The IRR remains negative at -6.31%, and the Payback Period extends beyond the investment's useful life, further reducing the attractiveness of this investment.

Limitations of Analysis

The primary limitation of the analysis is the assumption of uniform cash flows over ten years, which overlooks potential market demand growth that could improve cash inflows. Additionally, the analysis does not consider the potential benefits of operational efficiencies or other strategic advantages that could arise from the investment, which might positively impact the project's long-term viability. Furthermore, Germany has a high GDP and a growing economy, which could present opportunities for increased market demand and better financial outcomes over time.

Recommendation

Investment A is **not recommended** due to its negative NPV, low IRR, and poor PI. The project fails to meet the minimum financial benchmarks needed to justify the investment, and financing costs further degrade its viability. The negative NPV indicates that the project will not generate sufficient returns to cover its costs, while the low IRR and PI confirm that the expected profitability is inadequate. Furthermore, the cash flows would need to increase by more than 50% for the investment to become viable. Given the lack of demonstrated profitability and the high risks associated with the project, it is not advisable for Med-I-Mark to proceed with Investment A.

Investment B: Acquire Competitor Assets in Australia

Investment B (Acquire Australia)			
Initial Investment	**Cash Flow**	**Undiscounted Cash Flow**	**After-tax Debt Cost**
($17,000,000)	$3,000,000/$5,000,000	$23,000,000	4.8%
Metric	**Base**	**With Financing**	**After Taxes**
NPV	$335,330	($3,626,699)	($6,677,176)
IRR	14.40%	9.57%	5.36%
MIRR	14.20%	11.59%	9.13%
PI	1.02	0.81	0.65
DSCR	5.27	4.27	3.41

Investment B involves acquiring the assets of a competitor in Australia, which has a 70% share in a highly profitable market. With an initial investment cost of $17 million and a 70/30 bond to stock ratio, the total bond funding needed would be $12,659,574, and the stock funding needed would be $6,219,512 after considering par rate costs. In the first five years the cash flow is $3 million, then increasing to $5 million in the next five years. The undiscounted cash flow is $23 million, and the after-tax cost of debt is 4.8%.

Base Case

Upon analysis, the NPV of Investment B was calculated to be $335,330, suggesting a slight positive impact on shareholder value. The IRR is 14.40%, which meets the required rate of return of 14%. The PI stands at 1.02, indicating that the project is marginally profitable. The DSCR for this investment is 8.95, showing a strong ability to cover debt obligations from operating cash flows, which adds confidence to its financial stability.

With Financing

The annual interest payment on the bonds is $759,574, calculated using an interest rate of 6%. Under the financing scenario, the NPV, calculated with the Required Rate of Return, decreases compared to the Base Case, resulting in an NPV of -$3,626,699. The IRR also drops to 9.57%, which falls below the required rate of return, raising concerns about its viability. The PI, also calculated with the Required Rate of Return, decreases to 0.81, showing reduced profitability when interest is considered. The DSCR also declines to 7.25, indicating a reduced but still reasonable capacity to cover debt obligations. Overall, the financing worsens the project's financial metrics, making it less attractive, though it remains strategically sound.

After Taxes

After considering the tax impact, the effective cash flow reduces, making the project more sensitive to variation in cash inflows. The IRR falls to 5.36%, which is below the required rate of return. Despite these challenges, the project remains strategically important for market expansion, providing potential long-term benefits. However, the financial metrics suggest

increased risk, including a lower margin of safety for covering financing obligations. This sensitivity to fluctuating cash flows could result in significant challenges if market conditions do not meet expectations.

Limitations of Analysis

The primary limitation of the analysis is the assumption that cash flows will grow significantly in years 6-10. If this growth does not materialize, the investment may yield a negative NPV. Additionally, there could be unexpected challenges in acquiring such a large market share, which might impact cash flow realization. Furthermore, the analysis does not factor in potential synergies that may be realized from acquiring the competitor, which could improve the overall returns.

Recommendation

Investment B is **recommended** with caution due to its marginal profitability and strategic value. The project brings potential market expansion, but the narrow margin of profitability and sensitivity to projected cash flow growth present significant risks. The cash flows would need to increase by more than 20% for the investment to provide more comfortable returns. Med-I-Mark should proceed carefully, considering these risks in future planning.

Investment C: Bring New Product to Market

Investment C (New Product)			
Initial Investment	**Cash Flow**	**Undiscounted Cash Flow**	**After-tax Debt Cost**
($4,500,000)	$8,000,000	$35,500,000	6.4%
Metric	**Base**	**With Financing**	**After Taxes**
NPV	$22,964,648	$21,728,739	$16,482,991
IRR	176.68%	168.56%	133.88%
MIRR	36.60%	35.98%	32.98%
PI	6.10	5.83	4.66
DSCR	22.22	21.22	16.98

Investment C involves launching a new medical device already in late-stage development, an implanted drug delivery system capable of being programmed via a smartphone. This product has the potential to transform Med-I-Mark's market position. The initial investment required is $4.5 million, financed entirely through a line of credit. The undiscounted cash flow is $35 million and the after-tax cost of debt it 6.4%.

Base Case

The analysis yields an impressive NPV of $22,964,648, indicating a substantial positive impact on shareholder value. The IRR of 176.68% and PI of 6.10 are highly favorable, demonstrating both a quick and substantial return on investment.

With Financing

The financing for Investment C involves a $4.5 million line of credit with an interest cost of $360,000 annually from the 8% interest rate. Under this scenario, the NPV remains strong at $21,728,739, while the IRR decreases slightly to 168.56%, which still far exceeds the required rate of return. The PI also remains robust at 5.83, indicating substantial profitability.

After Taxes

After accounting for taxes, the effective cash flow remains significantly profitable. The NPV stands at $16,482,991, and the IRR, is still impressive at 133.88% These metrics show that even after financing and taxation, the investment maintains its attractiveness.

Limitations of Analysis

The primary limitation of the analysis is the assumption of such high cash flows without accounting for other potential complications or additional costs. The analysis assumes that the market will continue to accept and demand the new product at the projected rate, without any significant disruptions. Additionally, rapid technological advancements could result in a competitor introducing a superior product, which would render the investment obsolete more quickly than anticipated. There is also a risk that cash flows may gradually decrease over time rather than remain consistent, which would significantly affect the financial outlook of the project.

Recommendation

Investment C is **highly recommended** due to its strong financial metrics, rapid payback, and the strategic value it adds by launching an innovative product. The project demonstrates considerable profitability under all scenarios, making it the most attractive investment opportunity among the options considered. Even if cash flows are cut in half the NPV would remain positive. However, it is important for Med-I-Mark to consider the relatively short five-year product lifecycle and invest in ongoing innovation to continue market dominance.

Investment D: Enhance Existing Products

Investment D (Enhance Products) Stock Financing			
Initial Investment	**Cash Flow**	**Undiscounted Cash Flow**	**After-tax Debt Cost**
($3,000,000)	$600,000	$3,000,000	6.4%
Metric	**Base**	**With Financing**	**After Taxes**
NPV	($528,867)	($528,867)	($1,154,801)
IRR	10.18%	10.18%	5.27%
MIRR	12.23%	12.23%	9.76%
PI	0.86	0.86	0.68
DSCR	N/A	N/A	N/A

Investment D (Enhance Products) Line of Credit Financing			
Initial Investment	**Cash Flow**	**Undiscounted Cash Flow**	**After-tax Debt Cost**
($3,000,000)	$600,000	$3,000,000	6.4%
Metric	**Base**	**With Financing**	**After Taxes**
NPV	$129,669	($1,122,198)	($1,497,759)
IRR	15.10%	3.46%	-0.74%
MIRR	14.48%	8.78%	6.38%
PI	1.04	0.63	0.50
DSCR	2.50	1.50	1.20

Investment D involves enhancing existing orthopedic trauma products, a core part of Med-I-Mark's business. The initial investment required is $3 million, with incremental cash flows of $600,000 annually for ten years. This investment presents a unique situation, and because of that, it will be analyzed through both line of credit financing as well as stock financing. The undiscounted cash flow is $3 million, and the after-tax cost of debt is 6.4%.

Base Case

The NPV of investment D is calculated at $129,669, indicating a marginal positive return. The IRR is 15.10%, which initially exceeds the required rate of return. However, the PI is relatively low at 1.04, suggesting limited profitability. The modest NPV and PI indicate that the project is just barely worth the investment, and while the IRR exceeds the required return, the overall profitability remains constrained. The DSCR with a line of credit financing is a meager 2.50 suggesting a very low return on interest payments.

With Financing

The financing can be based on either a line of credit or stock issuance, and the results vary accordingly. When using a $3 million line of credit, the annual interest cost is $240,000. Under this scenario, the NPV becomes negative at -$1,122,198, and the IRR drops to 3.46%, which is significantly below the required rate of return. The PI also falls to 0.63, indicating limited profitability, and the DSCR declines to 1.50, reflecting tighter margins for covering debt obligations. In contrast, when financed through stock, the NPV is calculated to be -$528,867, the IRR is 10.18, and PI under stock financing is 0.86. Although these numbers drop below the required return threshold, the numbers hold fairly strong.

After Taxes

After considering taxes, the IRR for the line of credit financing drops further to -0.74%, rendering the project unattractive under current financing conditions. In contrast, with stock financing, the after-tax IRR is still 5.27 %, which is still relatively favorable, especially compared to debt financing. The reduced after-tax cash flows highlight the vulnerability of this project to interest rate increases and taxation effects if financed through a line of credit. The project becomes highly sensitive to minor fluctuations in cash inflows, increasing the associated risk when using debt. On the other hand, stock financing provides a more stable outlook as it eliminates the interest burden, allowing for better cash flow management and reduced sensitivity to interest rate changes.

Limitations of Analysis

The primary limitation of the analysis is that it does not account for potential improvements in production efficiency or other cost-saving measures that could improve profitability. Additionally, the assumption of steady cash flows over the ten-year period may not reflect potential changes in market demand, competitive pressures, or operational disruptions that could impact the expected returns. Market demand can be volatile, and shifts in customer preferences or technological advancements could significantly affect cash flows. Additionally, the analysis assumes no unexpected regulatory, supply chain, or operational challenges, which are common and could impose additional costs or delays. The impact of these factors could lead to lower profitability than initially projected, affecting the overall financial viability of the investment. Furthermore, the analysis assumes that costs associated with production enhancements remain constant, which may not be realistic given potential increases in material costs, labor expenses, or other variable costs. This could result in narrower profit margins and reduced overall returns from the investment.

Recommendation

Investment D is not recommended for funding through a line of credit due to its poor financial performance under both the financing and after-tax scenarios. However, it is **recommended** pursuing this investment if it is financed either through available cash or stock financing. Without the burden of interest expense, Investment D generates reasonable returns and shows potential for adding value to Med-I-Mark. The financial metrics indicate that while the project struggles with the additional cost of financing it could still offer positive returns under non-debt financing options.

Conclusion

After evaluating the four investment opportunities for Med-I-Mark Tech Ltd, Investment A (upgrading German facilities) is not recommended due to negative NPV and financing risks. Investment B (acquiring competitor assets in Australia) offers strategic growth but has narrow profitability, so it should be approached cautiously. Investment C (launching a new medical device) is highly recommended, with strong financial metrics, rapid payback, and market potential despite a short product lifecycle. Investment D (enhancing existing products) is not recommended with debt financing but is viable with cash or stock funding due to better performance without interest costs.

The total financing required for all recommended investments includes $12,660,000 in bonds, $9,878,100 in stock, and $4,500,000 in line of credit, resulting in a combined debt of $27,038,100. The total interest burden amounts to $1,119,600 annually. These final financing figures emphasize the need for Med-I-Mark to allocate capital efficiently and manage financial risks carefully to achieve sustainable growth.